General
Preferred name
mobocertinib
Synonyms
tak788 ()
TAK-788 ()
Mobocertinib (succinate) ()
AP32788 ()
TAK-788 (succinate) ()
AP32788 (succinate) ()
Mobocertinib (TAK788) ()
MOBOCERTINIB SUCCINATE ()
AP-32788 ()
AP32788 SUCCINATE ()
TAK-788 SUCCINATE ()
AP-32788 SUCCINATE ()
Exkivity ()
P&D ID
PD055118
CAS
1847461-43-1
2389149-74-8
Tags
available
drug
Approved by
FDA
First approval
2021
Drug indication
Liver disease
Non-small cell lung cancer
non-small cell lung carcinoma
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mobocertinib (TAK-788) is an oral EGFR/HER2 tyrosine kinase inhibitor that is claimed in Ariad Pharmaceuticals' patent WO2015195228A1 . It inhibits EGFR and HER2 with activating/resistance mutations, including rare EGFR Ins20 (exon 20 insertion) resistance mutations and was progressed by Takeda Pharmaceuticals as an advanced therapy for metastatic NSCLC with this exon 20 insertion .
(GtoPdb)
DESCRIPTION
Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research[1][2].
PRICE
49
DESCRIPTION
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research[1][2].
DESCRIPTION
On September 2021, FDA approved mobocertinib to treat ocally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
(PKIDB)
DESCRIPTION
Mobocertinib is an effective and orally active inhibitor of EGFR and HER2 oncogenic mutants. Anti-tumor activity.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Mobocertinib (tak788) is a potent inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
15
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
PKIDB
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
585.31
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
2
Rotatable Bonds
12
Ring Count
4
Aromatic Ring Count
4
cLogP
5.08
TPSA
113.85
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
EGFR
EGFR/HER2 inhibitor
EGFR,HER2
Pathway
JAK/STAT Signaling
Protein Tyrosine Kinase/RTK
Angiogenesis
Tyrosine Kinase/Adaptors
Solubility
Soluble in DMSO
Source data
